Sigma Planning Corp’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.55M | Buy |
2,012
+1,238
| +160% | +$948K | 0.04% | 412 |
|
|
2025
Q4 | $597K | Buy |
774
+260
| +51% | +$177K | 0.02% | 733 |
|
|
2025
Q3 | $289K | Sell |
514
-117
| -19% | -$66.2K | 0.01% | 1043 |
|
|
2025
Q2 | $331K | Sell |
631
-158
| -20% | -$88.2K | 0.01% | 955 |
|
|
2025
Q1 | $500K | Buy |
789
+7
| +0.9% | +$4.82K | 0.02% | 737 |
|
|
2024
Q4 | $557K | Buy |
782
+373
| +91% | +$313K | 0.02% | 694 |
|
|
2024
Q3 | $430K | Buy |
409
+16
| +4% | +$17.8K | 0.01% | 797 |
|
|
2024
Q2 | $413K | Buy |
393
+25
| +7% | +$24.2K | 0.01% | 804 |
|
|
2024
Q1 | $354K | Buy |
+368
| New | +$350K | 0.01% | 884 |
|
|
2023
Q4 | – | Sell |
-385
| Closed | -$317K | – | 1107 |
|
|
2023
Q3 | $317K | Sell |
385
-70
| -15% | -$55K | 0.01% | 899 |
|
|
2023
Q2 | $327K | Sell |
455
-32
| -7% | -$24.7K | 0.01% | 903 |
|
|
2023
Q1 | $400K | Sell |
487
-148
| -23% | -$112K | 0.01% | 891 |
|
|
2022
Q4 | $458K | Buy |
635
+142
| +29% | +$105K | 0.02% | 791 |
|
|
2022
Q3 | $340K | Sell |
493
-53
| -10% | -$33.4K | 0.01% | 903 |
|
|
2022
Q2 | $323K | Sell |
546
-8
| -1% | -$5.2K | 0.01% | 957 |
|
|
2022
Q1 | $387K | Sell |
554
-96
| -15% | -$60.7K | 0.01% | 952 |
|
|
2021
Q4 | $410K | Buy |
650
+67
| +11% | +$41.2K | 0.01% | 929 |
|
|
2021
Q3 | $353K | Sell |
583
-753
| -56% | -$467K | 0.01% | 975 |
|
|
2021
Q2 | $746K | Sell |
1,336
-133
| -9% | -$67.4K | 0.02% | 658 |
|
|
2021
Q1 | $695K | Buy |
1,469
+274
| +23% | +$133K | 0.02% | 632 |
|
|
2020
Q4 | $577K | Sell |
1,195
-138
| -10% | -$74.5K | 0.02% | 642 |
|
|
2020
Q3 | $746K | Sell |
1,333
-3,689
| -73% | -$2.24M | 0.03% | 479 |
|
|
2020
Q2 | $3.13M | Buy |
5,022
+4,173
| +492% | +$2.37M | 0.14% | 160 |
|
|
2020
Q1 | $415K | Sell |
849
-525
| -38% | -$217K | 0.02% | 548 |
|
|
2019
Q4 | $516K | Buy |
1,374
+85
| +7% | +$28.6K | 0.02% | 588 |
|
|
2019
Q3 | $358K | Buy |
1,289
+254
| +25% | +$75.2K | 0.02% | 701 |
|
|
2019
Q2 | $324K | Buy |
+1,035
| New | +$345K | 0.02% | 700 |
|
|
2018
Q4 | – | Sell |
-781
| Closed | -$316K | – | 950 |
|
|
2018
Q3 | $316K | Sell |
781
-78
| -9% | -$29.7K | 0.02% | 663 |
|
|
2018
Q2 | $296K | Buy |
859
+265
| +45% | +$82.9K | 0.02% | 654 |
|
|
2018
Q1 | $205K | Buy |
+594
| New | +$207K | 0.02% | 770 |
|
Other funds holding REGN
VCM
N
Sigma Planning Corp's REGN Position: Q1 2026 in Review
Sigma Planning Corp increased its Regeneron Pharmaceuticals (REGN) stake by 160% in Q1 2026, buying an estimated $948K and bringing the position to 2,012 shares worth $1.55M. The position accounts for 0.04% of the portfolio, ranked #412.
Sigma Planning Corp first reported a position in REGN in Q1 2018 and has held it in 30 quarters since. The position peaked at $3.13M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Sigma Planning Corp held 2,012 shares of Regeneron Pharmaceuticals worth $1.55M as of Q1 2026.
- Sigma Planning Corp bought 1,238 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $948K.
- Regeneron Pharmaceuticals made up 0.04% of Sigma Planning Corp's portfolio in Q1 2026, its #412 holding.
- Sigma Planning Corp first reported a position in Regeneron Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
- Sigma Planning Corp's Regeneron Pharmaceuticals position peaked at $3.13M in Q2 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.